Can a targeted nerve block outsmart pancreatic cancer pain?
NCT ID NCT00974948
First seen Aug 14, 2026 · Last updated Aug 14, 2026
Summary
This trial tests whether an ultrasound-guided injection of alcohol and a numbing agent around the celiac ganglia can relieve pain in people newly diagnosed with inoperable pancreatic cancer. Participants receive either the nerve block or a sham procedure, alongside standard pain management. The study compares pain scores, opioid use, quality of life, and survival over three months to see if early nerve destruction can prevent pain from escalating.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- EUS-guided celiac plexus neurolysis (injection of alcohol and bupivacaine around the celiac ganglia)
- What this could lead to
- If effective, this procedure could offer a new way to control pain early in pancreatic cancer, potentially reducing the need for strong narcotics and improving quality of life.
- What could go wrong
- The procedure is invasive and carries risks like bleeding or nerve damage. It may not provide better pain relief than standard narcotics, and the trial is still in phase 3, so results are not yet confirmed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INOPERABLE PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHUM
Montreal, Quebec, H2X 3J4, Canada